Crimson Merger Sub I

DICE Therapeutics is a biopharmaceutical company focused on developing oral small molecule therapies for chronic immunological and inflammatory diseases. The company utilizes its proprietary DELSCAPE platform, a DNA-encoded library technology, to discover selective small molecules that can modulate protein-protein interactions, a challenge typically addressed by injectable biologics. Its lead program, DC-806, is an oral antagonist of the pro-inflammatory cytokine IL-17, which reached Phase 2 clinical trials for the treatment of psoriasis. In August 2023, DICE was acquired by Eli Lilly for approximately $2.4 billion to strengthen Lilly's immunology pipeline with oral alternatives to existing treatments. The company's portfolio also includes second-generation IL-17 inhibitors and early-stage programs targeting various integrins.